Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna

MT Newswires Live06-23

Phathom Pharmaceuticals (PHAT) said Tuesday it has completed the enrollment in its phase 2 clinical trial evaluating Voquezna, or vonoprazan, as a potential treatment for eosinophilic esophagitis, a chronic inflammatory disease of the esophagus.

The study enrolled 95 adult patients across 41 US clinical sites and is assessing the drug as a non-steroidal oral therapy. Topline results are expected in Q4, the company said.

Phathom said the trial could help determine whether its acid suppression therapy offers a new treatment approach for patients who currently rely on proton pump inhibitors, which are not approved for the condition.

If the results are positive, the company said it plans to engage with US regulators on further development, including potential pediatric studies and broader indications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment